Innoviva Inc
NASDAQ:INVA

Watchlist Manager
Innoviva Inc Logo
Innoviva Inc
NASDAQ:INVA
Watchlist
Price: 17.78 USD -0.06%
Market Cap: 1.1B USD
Have any thoughts about
Innoviva Inc?
Write Note

Innoviva Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Innoviva Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Innoviva Inc
NASDAQ:INVA
Net Change in Cash
$80.7m
CAGR 3-Years
N/A
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Net Change in Cash
$252m
CAGR 3-Years
N/A
CAGR 5-Years
5%
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Net Change in Cash
$325m
CAGR 3-Years
N/A
CAGR 5-Years
-58%
CAGR 10-Years
-20%
Pfizer Inc
NYSE:PFE
Net Change in Cash
-$1.6B
CAGR 3-Years
N/A
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Net Change in Cash
$6B
CAGR 3-Years
31%
CAGR 5-Years
169%
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Net Change in Cash
$988.2m
CAGR 3-Years
72%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Innoviva Inc
Glance View

Market Cap
1.1B USD
Industry
Pharmaceuticals

In the heart of Silicon Valley, Innoviva Inc. has carved out a niche within the pharmaceutical landscape, balancing the art of innovation with the demands of modern healthcare economics. Initially emerging as a dynamic player in drug development, Innoviva made a strategic pivot to focus on the monetization and management of its royalties and collaborations. The company's primary revenue stream flows from partnerships with GlaxoSmithKline (GSK), stemming from co-developed respiratory treatments like the inhaled medications Trelegy and Anoro Ellipta. These partnerships provide Innoviva with steady royalty income based on product sales, allowing it to operate with a lean but effective business model, focusing on maximizing value from its existing assets rather than pursuing the expensive and risky path of drug discovery and development. Beyond merely basking in the comfort of predictable cash flows, Innoviva has tactically reinvested its earnings to fuel further growth and diversification. The company has been channeling resources into acquiring new assets and entering joint ventures that align with its core expertise and long-term vision. This approach not only broadens its portfolio but also hedges against the inherent risks associated with dependency on a limited number of revenue sources. By leveraging its financial strength and strategic partnerships, Innoviva has positioned itself as a nimble player in the pharmaceutical sector, adept at extracting maximum value through prudent financial management and strategic foresight.

INVA Intrinsic Value
22.34 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

What is Innoviva Inc's Net Change in Cash?
Net Change in Cash
80.7m USD

Based on the financial report for Sep 30, 2024, Innoviva Inc's Net Change in Cash amounts to 80.7m USD.

What is Innoviva Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
-8%

Back to Top